Ertapenem: A parenteral, long-acting carbapenem

Clinical Microbiology Newsletter

Volumn 25, Issue 12, 2003, Pages 89-95

  Motyl, Mary ^a   Mixson, Lori ^a   Friedland, Ian R ^a   Woods, Gail L ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTRIAXONE; ERTAPENEM; PIPERACILLIN PLUS TAZOBACTAM;

ABDOMINAL INFECTION; ACINETOBACTER; AEROMONAS HYDROPHILA; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; BACTERIAL PNEUMONIA; BACTEROIDES FRAGILIS; BETA HEMOLYTIC STREPTOCOCCUS; BILOPHILA WADSWORTHIA; BURKHOLDERIA; CLINICAL TRIAL; CORYNEBACTERIUM; CREATININE CLEARANCE; DOSE KIDNEY FUNCTION RELATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG STRUCTURE; ENTEROBACTERIACEAE; HAEMOPHILUS; HUMAN; KLEBSIELLA PNEUMONIAE; LACTOBACILLUS CASEI; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; PELVIC INFLAMMATORY DISEASE; PSEUDOMONAS AERUGINOSA; REVIEW; SKIN INFECTION; STENOTROPHOMONAS MALTOPHILIA; STREPTOCOCCUS PNEUMONIAE; URINARY TRACT INFECTION;

EID: 0037975576     PISSN: 01964399     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0196-4399(03)80030-2     Document Type: Review

References (29)

1. NCCLS. 2001. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 5th ed. NCCLS document M7-A5. NCCLS, Wayne, PA.
2. NCCLS. 2001. Methods for antimicrobial susceptibility testing of anaerobic bacteria, 5th ed. Approved standard M11-A5. NCCLS, Wayne, PA.
3. NCCLS. 2003. Performance standard for antimicrobial susceptibility testing: disk diffusion. Document M100-S13 (M2). NCCLS, Wayne, PA.
4. Livermore, D.M. et al. 2001. In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia. Antimicrob. Agents Chemother. 45:1860-1867.
5. Fuchs, P.C. et al. 2001. In vitro activities of ertapenem (MK-0826) against clinical bacterial isolates from 11 North American medical centers. Antimicrob. Agents Chemother. 45:1915-1918.
6. Goldstein, E.J.C. et al. 2000. Comparative in vitro activities of ertapenem (MK-0826) against 1,001 anaerobes isolated from human intra-abdominal infections. Antimicrob. Agents Chemother. 44:2389-2394.
7. Goldstein, E.J.C. et al. 2002. General microbiology and in vitro susceptibility of anaerobes isolated from complicated skin and skin-structure infections in patients enrolled in a comparative trial of ertapenem versus piperacillintazobactam. Clin. Infect. Dis. 35(Suppl.1):S119-S125.
8. Pelak, B.A. et al. 2002. In vitro activities of ertapenem against aerobic bacterial pathogens isolated from patients with complicated intra-abdominal infections. J. Chemother. 14:227-233.
9. Pelak, B.A. et al. 2002. Comparative in vitro activities of ertapenem against aerobic and facultative bacterial pathogens from patients with complicated skin and skin structure infections. Diagn. Microbiol. Infect. Dis. 43:129-133.
10. Pelak, B.A. et al. 2002. Comparative in vitro activities of ertapenem against bacterial pathogens from patients with acute pelvic infection. J. Antimicrob. Chemother. 50:735-741.
11. Hicks, P.S. et al. 2002. Comparative in vitro activity of ertapenem against bacterial pathogens isolated from patients with lower respiratory tract infections. Clin. Microbiol. Infect. 8:753-757.
12. Kohler, J. et al. 1999. In vitro activities of the potent, broad-spectrum carbapenem MK-0826 (L-749,345) against broad-spectrum β-lactamase- and extended-spectrum β-lactamase-producing Klebsiella pneumoniae and Escherichia coli clinical isolates. Antimicrob. Agents Chemother. 43:1170-1176.
13. Jones, R.N. 2001. In vitro evaluation of ertapenem (MK-0826), a long-acting carbapenem, tested against selected resistant strains. J. Chemother. 13:363-376.
14. Livermore, D.M. et al. 2001. Activity of ertapenem (MK-0826) versus Enterobacteriaceae with potent β-lactamases. Antimicrob. Agents Chemother. 45:2831-2837.
15. Dorso, K.L. et al. 2002. In vitro kill rates of ertapenem, ceftriaxone, and piperacillin-tazobactam against intraabdominal pathogens, abstr. A- 156, p. 203. In Abstracts of the 102nd General Meeting of the American Society for Microbiology, American Society for Microbiology, Washington, D.C.
16. Friedland, I. et al. 2002. Use of surrogate antimicrobial agents to predict susceptibility to ertapenem. Diagn. Microbiol. Infect. Dis. 43:61-64.
17. Majumdar, A.K. et al. 2002. Pharmacokinetics of ertapenem in healthy young volunteers. Antimicrob. Agents Chemother. 46:3506-3511.
18. Walker, R. et al. 1994. Pharmacodynamic activities of meropenem in an animal model, abstr. A91. In Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
19. van Ogtrop, M.L. et al. 1998. In vivo antimicrobial activity of MK-0826, a new carbapenem, against various penicillin-resistant pneumococci, abstr. F 48. In Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
20. van Ogtrop, M.L. et al. 1999. In vivo antimicrobial activity of MK-0826, a new carbapenem, against various gram-negative bacteria and Staphylococcus aureus, abstr. 999. In Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
21. Data on file at Merck & Co., Inc.
22. Friedland, I. et al. 2002. In vitro activity of ertapenem against common clinical isolates in relation to human pharmacokinetics. J. Chemother. 14:483-491.
23. Graham, D. et al. 2002. Once a day ertapenem versus four daily doses of piperacillin-tazobactam for treatment of complicated skin and skin structure infections in adults: results of a prospective, randomized, double-blind multicenter study. Clin. Infect. Dis. 34:1460-1468.
24. Ortiz-Ruiz, G. et al. 2002. A prospective, multicenter, double-blind, randomized, comparative study to evaluate the safety, tolerability, and efficacy of ertapenem versus ceftriaxone in the treatment of community-acquired pneumonia in adults. Clin. Infect. Dis. 34:1076-1083.
25. Jimenez-Cruz, F. et al. 2002. A prospective, multicenter, randomized, double-blind study comparing ertapenem and ceftriaxone followed by appropriate oral therapy for treatment of complicated urinary tract infections in adults. Urology 60:16-22.
26. Solomkin, J. et al. 2003. Results of a double-blind, randomized, comparative trial of ertapenem vs. piperacillin/ tazobactam in the treatment of complicated intraabdominal infections. Ann. Surg. 237:235-245.
27. Roy, S. et al. 2003. Ertapenem once a day versus piperacillin-tazobactam every 6 hours for treatment of acute pelvic infections: a prospective, multi-center, randomized double-blind study. Infect. Dis. Obstet. Gynecol. 11:1-11.
28. Tomera, K. et al. 2002. Ertapenem versus ceftriaxone followed by appropriate oral therapy for treatment of complicated urinary tract infections in adults: results of a prospective, randomized, double-blind multicenter study. Antimicrob. Agents Chemother. 46:2895-2900.
29. Vetter, N. et al. 2002. A prospective, randomized, double-blind multicenter comparison of parenteral ertapenem and ceftriaxone for treatment of hospitalized adults with community-acquired pneumonia. Clin. Ther. 24:1770-1785.